Skip to main content
Prof. Hartmann interviewed by Dr. Barbara Kreppel for 'Angewandte Nuklearmedizin'

Publication

Immunology and Nuclear Medicine

Prof. Gunther Hartmann was interviewed for the magazine “Angewandte Nuklearmedizin” and answered questions about immunology and nuclear medicine.

Dr. Barbara Kreppel from the magazine “Angewandte Nuklearmedizin” interviewed Prof. Gunther Hartmann, director of the Institute of Clinical Chemistry and Clinical Pharmacology and founding speaker of the ImmunoSensation2 Cluster of Excellence, on his expertise on immunology and nuclear medicine. 

During the interview, Prof. Gunther Hartmann shed light on emerging trends in the research fields of immune-oncology and autoimmunity, emphasizing the potential of nuclear medicine for the development of diagnostic tools and novel therapies. He gave an interesting perspective on how nuclear medicine advancements could help with cancer therapy and highlighted the importance of nuclear medicine for immune imaging.

The full interview can be found in the latest issue of “Angewandte Nuklearmedizin”.

Interview:

Angewandte Nuklearmedizin 2024; 47: 78–79
DOI 10.1055/a-2183-2133
ISSN 2749-7445
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14,
70469 Stuttgart, Germany

Press contact:

Dr. Barbara Kreppel
Universitätsklinikum Bonn
Klinik und Poliklinik für Nuklearmedizin
Venusberg-Campus 1
53127 Bonn
E-Mail: barbara.kreppel@ukbonn.de

Related news

The human P2X4 receptor

Publication

A starting point for the development of new pain and cancer drugs

—The human P2X4 receptor plays an important role in chronic pain, inflammation and some types of cancer. Researchers at the University of Bonn and the University Hospital Bonn (UKB) have now discovered a mechanism that can inhibit this receptor. The results were recently published in the scientific journal Nature Communications and open up a pathway for the development of new drugs. A study carried out by the University of Bonn and the University Hospital Bonn throws light on how P2X2 can be inhibited. The results have recently been published in Nature Communications.
View entry
Kato research group

Publication

Ominous false alarm in the kidney

—Bonn researchers have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction. In cooperation with Nanyang Technological University Singapore and the University Hospital Würzburg, among others, the study provides an explanation for how a point mutation in the immune receptor RIG-I transforms the body's defense system into a self-destructive force and causes severe organ-specific autoimmune diseases. The results have now been published in the journal Science Immunology.
View entry
News_Proebstel

Publication

Unique immune signatures to distinguish MOGAD from MS

—Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body’s immune system mistakenly attacks the protective myelin sheath of nerve fibers in the central nervous system. Although MOGAD induces symptoms similar to multiple sclerosis (MS), its underlying biology appears to be fundamentally different. Understanding these distinctions is crucial for developing effective, disease-specific treatments. A new international study now sheds light on these immune differences.
View entry

Back to the news overview